ArticleFrontiers in medicine2026

Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS.

Tao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.